DS
CRSP icon

David Shaw’s CRISPR Therapeutics CRSP Stock Holding History

David Shaw’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$333K Buy
+6,100
New +$322K ﹤0.01% 4367
2026
Q1 		– Sell
-30,200
Closed -$1.58M – 4623
2025
Q4 		$1.58M Sell
30,200
-40,000
-57% -$2.4M ﹤0.01% 3226
2025
Q3 		$4.55M Buy
+70,200
New +$4.03M ﹤0.01% 2311
2024
Q4 		– Sell
-35,500
Closed -$1.67M – 4472
2024
Q3 		$1.67M Buy
35,500
+24,000
+209% +$1.22M ﹤0.01% 2854
2024
Q2 		$621K Sell
11,500
-1,600
-12% -$92.5K ﹤0.01% 3493
2024
Q1 		$893K Sell
13,100
-73,200
-85% -$5.24M ﹤0.01% 3163
2023
Q4 		$5.4M Buy
86,300
+76,300
+763% +$4.22M ﹤0.01% 1847
2023
Q3 		$454K Hold
10,000
– – ﹤0.01% 3464
2023
Q2 		$561K Sell
10,000
-20,000
-67% -$1.13M ﹤0.01% 3375
2023
Q1 		$1.36M Sell
30,000
-70,000
-70% -$3.4M ﹤0.01% 2950
2022
Q4 		$4.07M Buy
100,000
+40,000
+67% +$2.12M ﹤0.01% 2290
2022
Q3 		$3.92M Sell
60,000
-30,000
-33% -$2.17M ﹤0.01% 2357
2022
Q2 		$5.47M Sell
90,000
-40,000
-31% -$2.35M 0.01% 2014
2022
Q1 		$8.16M Buy
130,000
+60,000
+86% +$3.77M 0.01% 1799
2021
Q4 		$5.3M Buy
70,000
+56,000
+400% +$4.89M ﹤0.01% 2304
2021
Q3 		$1.57M Sell
14,000
-50,000
-78% -$6.28M ﹤0.01% 3235
2021
Q2 		$10.4M Sell
64,000
-61,500
-49% -$7.48M 0.01% 1468
2021
Q1 		$15.3M Buy
+125,500
New +$19M 0.01% 1094
2020
Q4 		– Sell
-20,000
Closed -$1.67M – 3953
2020
Q3 		$1.67M Hold
20,000
– – ﹤0.01% 2519
2020
Q2 		$1.47M Buy
+20,000
New +$1.17M ﹤0.01% 2648
2019
Q1 		– Sell
-30,000
Closed -$857K – 3643
2018
Q4 		$857K Buy
+30,000
New +$1.04M ﹤0.01% 2758

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

David Shaw's CRSP Position: Q2 2026 in Review

David Shaw opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 893,812 shares worth $48.7M. The stake represents 0.02% of the portfolio and ranks #774 among its holdings. This is a return to the name: David Shaw previously reported a position in CRSP as recently as Q3 2024.

David Shaw first reported a position in CRSP in Q1 2018 and has held it in 24 quarters since. 520 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • David Shaw held 893,812 shares of CRISPR Therapeutics worth $48.7M as of Q2 2026.
  • CRISPR Therapeutics was a new David Shaw position in Q2 2026.
  • CRISPR Therapeutics made up 0.02% of David Shaw's portfolio in Q2 2026, its #774 holding.
  • David Shaw first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 24 quarters since.
  • 520 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.